Mayo Clinic receives patent for GeneSight

Share this article:

 

The Mayo Clinic has received a patent for a new medication selection procedure. GeneSight uses a test to prioritize the selection of medications for patients with depression, chronic pain and other psychiatric disorders.

 

GeneSight tests for genetic variants that affect a patient's response to psychotropic and analgesic medications, allowing clinicians to make evidence-based decisions about drug selection.

 

The company said the tool should help skilled nursing facilities reduce their use of antipsychotics.

Share this article:
close

Next Article in Products

More in Products

FDA approves weight management drug

The U.S. Food and Drug Administration has approved Contrave as a treatment for chronic weight management. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation.

PDI introduces new swab

PDI introduces new swab

PDI has debuted the PrevanticsĀ® Device Swab, a chlorhexidine gluconate/alcohol solution that has received market authorization from the U.S. Food and Drug Administration for disinfecting needleless access sites prior to ...

Oregon Freeze Dry releases Easy Meal

Oregon Freeze Dry releases Easy Meal

A new brand from Oregon Freeze Dry is designed to help long-term care and other healthcare facilities prepare for a disaster.